← Back
Data updated: Mar 10, 2026
MADRIGAL
Infectious DiseaseMetabolicCardiovascular
MADRIGAL is a pharmaceutical company focused on Infectious Disease, Metabolic, Cardiovascular. Key products include REZDIFFRA.
2024
Since
1
Drugs
-
Trials
4
Approved (2yr)
Recent Activity
REZDIFFRA 2025-12-19
Labeling
REZDIFFRA 2025-12-19
Labeling
REZDIFFRA 2025-12-19
Labeling
REZDIFFRA 2024-03-14
Type 1 - New Molecular Entity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 75%
1 drugs Phase 3: 1 Phase 2: 2 Phase 1: 1
Metabolic 10%
0 drugs Phase 2: 1
Cardiovascular 10%
0 drugs Phase 2: 1
Gastroenterology 5%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic
B BRAUN specialty
Infectious Disease, Metabolic, Cardiovascular
QUAGEN specialty
Metabolic, Gastroenterology, Cardiovascular, Infectious Disease
APOTHECON specialty
Infectious Disease, Cardiovascular, Gastroenterology
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-03-14
- Latest
- 2025-12-19
- Applications
- 1